R86
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.350
- INFLAMMATORY_RESPONSE+0.300
- ESTROGEN_RESPONSE_EARLY+0.290
- WNT_BETA_CATENIN_SIGNALING+0.270
- NOTCH_SIGNALING+0.260
- COAGULATION+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- HYPOXIA+0.250
- APICAL_JUNCTION+0.220
- TGF_BETA_SIGNALING+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- PROTEIN_SECRETION-0.420
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.390
- INTERFERON_GAMMA_RESPONSE-0.340
- PANCREAS_BETA_CELLS-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.320
- FATTY_ACID_METABOLISM-0.280
- MTORC1_SIGNALING-0.260
- E2F_TARGETS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454741 | — | D | 0.834 |
| 2 | 3843de1d-0eaa-48af-be58-903fcf2e5f89 | — | — | 0.833 |
| 3 | C3N-02339 | — | cohortSQ1 | 0.781 |
| 4 | AUR-AER7-TTM4-A-1-1-R-A742-41 | — | E | 0.779 |
| 5 | R7 | — | — | 0.774 |
| 6 | R314 | — | — | 0.762 |
| 7 | 69d9a82b-5c37-45bd-a1cf-ffe1392e84fc | — | — | 0.759 |
| 8 | R236 | — | — | 0.757 |
| 9 | R168 | — | — | 0.755 |
| 10 | ERR2208910 | — | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |